Clinical Trials Logo

Diabetic Nephropathy Type 2 clinical trials

View clinical trials related to Diabetic Nephropathy Type 2.

Filter by:

NCT ID: NCT03502031 Recruiting - Clinical trials for Renal Insufficiency, Chronic

Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

MRA-ACE
Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

NephroNet proposes to examine whether combining Spironolactone with maximal RAAS blockade will further reduce urinary protein at one year and whether prolonged therapy (24 months) is able to slow the decline in GFR. Because of combination MRA and RAAS therapy significantly increases the risk for clinically significant hyperkalemia, we also plan to determine whether the addition of Patiromer to these patients facilitates the use of combination therapy and allows a larger proportion of diabetic patients the potential benefit of combination therapy on renal function.

NCT ID: NCT03445247 Recruiting - Clinical trials for Diabetic Nephropathy Type 2

Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

In the current study, we use extracorporeal low-intensity shockwave therapy (ESWT) to treat on patients with type 2 diabetes in stage 3-4 chronic kidney disease and see whether it can improve the proteinuria, renal function, and blood pressure compared to baseline and control group.